Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa L Johnson

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Cancer Discovery|September 22, 2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.
Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialSolange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Clinical Lung Cancer|March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA StudyAnna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyCharles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Cancer Discovery|September 22, 2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.
Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialSolange Peters, Byoung Chul Cho, Alexander V Luft, et al.
Clinical Lung Cancer|March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA StudyAnna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
The Lancet. Oncology|December 10, 2016
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyCharles M Rudin, M Catherine Pietanza, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
Pageof 10